Physician profile
Basil Z Khalaf
NPI 1285924142
$93,267.35
in general payments reported to CMS, 2019-2025
7 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.70 · 2022: $13K · 2023: $49K · 2024: $9,592 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $31K · Food and Beverage: $2,403 · Travel and Lodging: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,700.00 |
| Consulting Fee | $30,651.52 |
| Food and Beverage | $2,403.09 |
| Travel and Lodging | $1,017.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $64,133.04 | 2022-2025 | |
| Abbvie INC. | $28,600.04 | 2022-2024 | |
| Organogenesis INC. | $220.60 | 2020-2022 | |
| Kci USA, INC. | $175.80 | 2020-2023 | Activ.A.C., V.A.C. Veraflo Cleanse Choice |
| Astrazeneca Pharmaceuticals Lp | $74.55 | 2022 | |
| Mindray Ds USA, INC. | $49.06 | 2023 | Te X, Te7 Max |
| Cashflow Solutions, LLC | $14.26 | 2023 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Khalaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.